Case Study: Mapping Evoked Fields in Primary Motor and Sensory Areas via Magnetoencephalography in Tetraplegia

Devices interfacing with the brain through implantation in cortical or subcortical structures have great potential for restoration and rehabilitation in patients with sensory or motor dysfunction. Typical implantation surgeries are planned based on maps of brain activity generated from intact functi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neurology Vol. 12; p. 739693
Main Authors Foldes, Stephen T., Chandrasekaran, Santosh, Camerone, Joseph, Lowe, James, Ramdeo, Richard, Ebersole, John, Bouton, Chad E.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 24.09.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Devices interfacing with the brain through implantation in cortical or subcortical structures have great potential for restoration and rehabilitation in patients with sensory or motor dysfunction. Typical implantation surgeries are planned based on maps of brain activity generated from intact function. However, mapping brain activity for planning implantation surgeries is challenging in the target population due to abnormal residual function and, increasingly often, existing MRI-incompatible implanted hardware. Here, we present methods and results for mapping impaired somatosensory and motor function in an individual with paralysis and an existing brain–computer interface (BCI) device. Magnetoencephalography (MEG) was used to directly map the neural activity evoked during transcutaneous electrical stimulation and attempted movement of the impaired hand. Evoked fields were found to align with the expected anatomy and somatotopic organization. This approach may be valuable for guiding implants in other applications, such as cortical stimulation for pain and to improve implant targeting to help reduce the craniotomy size.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Rushna Ali, Spectrum Health, United States; John E. Downey, University of Chicago, United States
This article was submitted to Experimental Therapeutics, a section of the journal Frontiers in Neurology
Edited by: Mike Modo, University of Pittsburgh, United States
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2021.739693